keyword
https://read.qxmd.com/read/38652877/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative-breast-cancer-results-from-the-phase-i-tropion-pantumor01-study
#1
JOURNAL ARTICLE
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika P Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors...
April 23, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38652858/comparison-of-safety-and-treatment-continuity-of-palbociclib-and-abemaciclib-for-hormone-receptor-positive-her2-negative-metastatic-recurrent-breast-cancer
#2
JOURNAL ARTICLE
Makiko Go, Michio Kimura, Shiori Yamada, Eiseki Usami, Yoshihiro Noguchi, Tomoaki Yoshimura
Background : Appropriate adverse event (AE) management and maintenance of therapeutic intensity are necessary to achieve therapeutic benefits of CDK4/6 inhibitors (palbociclib and abemaciclib) in hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer. Objective : This study was aimed at clarifying the effect of AEs associated with palbociclib and abemaciclib on treatment. Methods : A total of 62 and 49 patients were prescribed palbociclib and abemaciclib, respectively, at our hospital from January 1, 2018 to June 30, 2023...
April 23, 2024: Journal of Pharmacy Practice
https://read.qxmd.com/read/38652736/increased-mortality-in-acromegaly-is-due-to-vascular-and-respiratory-disease-and-is-normalised-by-control-of-gh-levels-a-retrospective-analysis-from-the-uk-acromegaly-register-1970-2016
#3
JOURNAL ARTICLE
Steve Orme, Richard McNally, Peter W James, Jessica Davis, John Ayuk, Claire Higham, John Wass
CONTEXT: Epidemiological studies involving patients with acromegaly have yielded conflicting results regarding cancer incidence and causes of mortality in relation to control of growth hormone (GH) excess. OBJECTIVE: The objective of this retrospective cohort study is to clarify these questions and identify goals for treatment and monitoring patients. METHODS: We studied 1845 subjects from the UK Acromegaly Register (1970-2016), obtaining cancer standardised incidence rates (SIR) and all causes standardised mortality rates (SMR) from UK Office for National Statistics, to determine the relationship between causes of mortality-age at diagnosis, duration of disease, post-treatment and mean GH levels...
April 23, 2024: Clinical Endocrinology
https://read.qxmd.com/read/38652557/dna-damage-obesity-and-obesity-related-health-complications-what-are-new-data-telling-us
#4
JOURNAL ARTICLE
Marta Włodarczyk, Grażyna Nowicka
PURPOSE OF REVIEW: Obesity is associated with increased DNA damage, which may in turn contribute to the development of obesity-related complications. DNA damage can also affect adipocyte biology, resulting in increased adiposity. Carefully managed weight loss programs can reverse this process. This article surveys new data that support these contentions. RECENT FINDINGS: Whole exome sequencing analyses have identified rare variants linked to high BMI and adiposity...
April 22, 2024: Current Opinion in Clinical Nutrition and Metabolic Care
https://read.qxmd.com/read/38652426/antibody-drug-conjugates-in-urological-cancers-a-review-of-the-current-landscape
#5
REVIEW
Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna
PURPOSE OF REVIEW: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT FINDINGS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652425/navigating-breast-cancer-oligometastasis-and-oligoprogression-current-landscape-and-future-directions
#6
REVIEW
Stephanie M Yoon, Jose G Bazan
PURPOSE: We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease. KEY FINDINGS: Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38652271/exploring-the-effect-of-brca1-2-status-on-chemotherapy-induced-hematologic-toxicity-in-patients-with-ovarian-cancer
#7
JOURNAL ARTICLE
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
OBJECTIVE: BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based chemotherapy might be at higher risk of developing chemotherapy-induced hematologic toxicity...
April 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38652227/brazilin-actuates-ferroptosis-in-breast-cancer-cells-via-p53-slc7a11-gpx4-signaling-pathway
#8
JOURNAL ARTICLE
Dan He, Xiao-Ning Tan, Lin-Pei Li, Wen-Hui Gao, Xue-Fei Tian, Pu-Hua Zeng
OBJECTIVE: To investigate the mechanism of induction of ferroptosis by brazilin in breast cancer cells. METHODS: Breast cancer 4T1 cells were divided into 6 groups: control, brazilin 1/2 half maximal inhibitory concentration (IC50 ), IC50 , 2×IC50 , erastin (10 µg/mL) and capecitabine (10 µg/mL) groups. The effect of brazilin on the proliferation of 4T1 cells was detected by cell counting kit-8 assay, and the treatment dose of brazilin was screened...
April 23, 2024: Chinese Journal of Integrative Medicine
https://read.qxmd.com/read/38652168/effects-of-taxane-induced-peripheral-neuropathy-on-hand-dexterity-impairment-evaluation-of-quantitative-and-subjective-assessments
#9
JOURNAL ARTICLE
Masahiro Manfuku, Junichiro Inoue, Nobuki Yamanaka, Hiroe Kanamori, Kazuhiro Sumiyoshi, Michihiro Osumi
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) commonly involves hand dexterity impairment. However, the factors affecting hand dexterity impairment are unknown and there is currently no established treatment. The purpose of the current study was to clarify factors influencing hand dexterity impairment in taxane-induced peripheral neuropathy using subjective and objective assessments. METHODS: We assessed patient characteristics, treatment-related factors, subjective symptoms of CIPN (Patient Neurotoxicity Questionnaire [PNQ]), psychological symptoms, and upper limb dysfunction (Quick Disabilities of the Arm, Shoulder and Hand [Quick DASH])...
April 23, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38652046/shikonin-in-breast-cancer-treatment-a-comprehensive-review-of-molecular-pathways-and-innovative-strategies
#10
JOURNAL ARTICLE
Saeid Iranzadeh, Davood Dalil, Soroush Kohansal, Mahdi Isakhani
OBJECTIVES: Breast cancer is a prevalent disease that has a substantial impact on women's mortality rates. Shikonin, a naphthoquinone derived from Lithospermum erythrorhizon, has demonstrated substantial anticancer effects. This study aims to conduct a comprehensive review of the latest research findings regarding the therapeutic efficacy of shikonin in the context of breast cancer treatment, with a specific emphasis on elucidating the underlying molecular mechanisms. METHODS: A comprehensive literature review was conducted on shikonin and breast cancer by searching PubMed, Scopus, Web of Science, and Google Scholar databases...
April 23, 2024: Journal of Pharmacy and Pharmacology
https://read.qxmd.com/read/38651681/fulfilling-the-role-of-a-parent-while-undergoing-treatment-for-cancer-a-review-of-the-literature-and-the-potential-impact-of-childcare-support-on-cancer-outcomes
#11
JOURNAL ARTICLE
Kang Woo Kim, Mary Lopresti, Stephanie L Graff, Sabrina Witherby, Don S Dizon, Mary Anne Fenton
Breast cancer is the most prevalent malignancy among adolescents and young adults (AYAs). Despite the efficacy of chemotherapy, AYA patients contend with psychosocial challenges, including psychological distress and financial toxicity, exacerbated further by those with dependent children. Parenting responsibilities intersect with cancer care, impacting both family dynamics and treatment adherence. Despite recognized needs, however, the impact of parenting concerns or even parenting status and the presence of dependents has not been systematically addressed and there is a paucity of interventional research regarding patients with cancer as concomitant caregivers...
April 23, 2024: American Journal of Clinical Oncology
https://read.qxmd.com/read/38650124/resistance-exercise-and-skeletal-muscle-related-outcomes-in-patients-with-cancer-a-systematic-review
#12
JOURNAL ARTICLE
Dong-Woo Kang, Jacqueline K Dawson, Oscar Barnes, Rebekah L Wilson, Mary K Norris, Paola Gonzalo-Encabo, Cami N Christopher, Salvatore Ficarra, Christina M Dieli-Conwright
BACKGROUND: Skeletal muscle loss is prevalent throughout the cancer continuum and correlates with morbidity and mortality. Resistance exercise has been trialed to mitigate skeletal muscle loss. This systematic review summarizes and qualitatively synthesizes the effects of resistance exercise on muscle-related outcomes in adult cancer populations, including skeletal muscle mass, performance and muscle-related biomarkers. METHODS: The systematic review protocol was developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)...
April 23, 2024: Medicine and Science in Sports and Exercise
https://read.qxmd.com/read/38650031/nsabp-fb-10-a-phase-ib-ii-trial-evaluating-ado-trastuzumab-emtansine-t-dm1-with-neratinib-in-women-with-metastatic-her2-positive-breast-cancer
#13
JOURNAL ARTICLE
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Corey Lipchik, Melanie Finnigan, Rachel C Jankowitz, Mohamad A Salkeni, Sai K Maley, Shannon L Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J Nagy, Carmen J Allegra, Kelly Vehec, Norman Wolmark, Peter C Lucas, Ashok Srinivasan, Katherine L Pogue-Geile
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. This study extends these observations with in-depth analysis of molecular markers and mechanisms of resistance in additional patients. METHODS: Forty-nine HER2-positive patients (determined locally) who progressed on-treatment with trastuzumab + pertuzumab were enrolled in this phase Ib/II study...
April 22, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38649964/clustering-of-hr%C3%A2-%C3%A2-her2-breast-cancer-in-an-asian-cohort-is-driven-by-immune-phenotypes
#14
JOURNAL ARTICLE
Jia-Wern Pan, Mohana Ragu, Wei-Qin Chan, Siti Norhidayu Hasan, Tania Islam, Li-Ying Teoh, Suniza Jamaris, Mee-Hoong See, Cheng-Har Yip, Pathmanathan Rajadurai, Lai-Meng Looi, Nur Aishah Mohd Taib, Oscar M Rueda, Carlos Caldas, Suet-Feung Chin, Joanna Lim, Soo-Hwang Teo
Breast cancer exhibits significant heterogeneity, manifesting in various subtypes that are critical in guiding treatment decisions. This study aimed to investigate the existence of distinct subtypes of breast cancer within the Asian population, by analysing the transcriptomic profiles of 934 breast cancer patients from a Malaysian cohort. Our findings reveal that the HR + /HER2- breast cancer samples display a distinct clustering pattern based on immune phenotypes, rather than conforming to the conventional luminal A-luminal B paradigm previously reported in breast cancers from women of European descent...
April 22, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38649821/long-non-coding-rna-sox2ot-in-tamoxifen-resistant-breast-cancer
#15
JOURNAL ARTICLE
Jeeyeon Lee, Eun-Ae Kim, Jieun Kang, Yee Soo Chae, Ho Yong Park, Byeongju Kang, Soo Jung Lee, In Hee Lee, Ji-Young Park, Nora Jee-Young Park, Jin Hyang Jung
Hormone receptor (HR)-positive breast cancer can become aggressive after developing hormone-treatment resistance. This study elucidated the role of long non-coding RNA (lncRNA) SOX2OT in tamoxifen-resistant (TAMR) breast cancer and its potential interplay with the tumor microenvironment (TME). TAMR breast cancer cell lines TAMR-V and TAMR-H were compared with the luminal type A cell line (MCF-7). LncRNA expression was assessed via next-generation sequencing, RNA extraction, lncRNA profiling, and quantitative RT-qPCR...
April 22, 2024: BMC molecular and cell biology
https://read.qxmd.com/read/38649655/perspectives-for-the-clinical-application-of-ctdna-analysis-to-breast-cancer-drug-therapy
#16
JOURNAL ARTICLE
Tetsuhiro Yoshinami
Circulating tumor DNA (ctDNA) consists of DNA fragments released from cancer cells into the blood circulation with quick clearance. Analysis of ctDNA can enable real-time assessment of the presence of cancer cells and their genomic characteristics. Therefore, ctDNA is expected to be one of the most useful biomarkers for cancer. In recent years, several ultra-sensitive assays for ctDNA analysis have been developed, and many clinical trials are using these assays to investigate the efficacy of ctDNA-based therapeutic strategies...
April 23, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38649619/superior-suppression-of-serum-estrogens-during-neoadjuvant-breast-cancer-treatment-with-letrozole-compared-to-exemestane
#17
JOURNAL ARTICLE
Bjørn-Erik Bertelsen, Bjørg Almås, Kamilla Fjermeros, Kristin Viste, Stephanie Beate Geisler, Torill Sauer, Knut Selsås, Jürgen Geisler
PURPOSE: The aromatase inhibitor letrozole and the aromatase inactivator exemestane are two of the most pivotal cancer drugs used for endocrine treatment of ER-positive breast cancer in all phases of the disease. Although both drugs inhibit CYP19 (aromatase) and have been used for decades, a direct head-to-head, intra-patient-cross-over comparison of their ability to decrease estrogen synthesis in vivo is still lacking. METHODS: Postmenopausal breast cancer patients suitable for neoadjuvant endocrine therapy were randomized to receive either letrozole (2...
April 23, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38649618/racial-disparities-in-outcomes-of-patients-with-stage-i-iii-triple-negative-breast-cancer-after-adjuvant-chemotherapy-a-post-hoc-analysis-of-the-e5103-randomized-trial
#18
JOURNAL ARTICLE
Saskia Leonard, Alyssa N Jones, Lisa Newman, Mariana Chavez-MacGregor, Rachel A Freedman, Erica L Mayer, Elizabeth A Mittendorf, Tari A King, Olga Kantor
PURPOSE: Breast cancer mortality is higher in Black women than other racial groups. This difference has been partially attributed to a higher proportion of triple-negative breast cancer (TNBC). However, it is uncertain if survival disparities exist in racially diverse TNBC patients receiving similar treatments. Here, we examine racial differences in disease-related outcomes in TNBC patients treated on the E5103 clinical trial. METHODS: From 2007 to 2011, 4,994 patients with stage I-III HER2-negative breast cancer were randomized to adjuvant chemotherapy with or without bevacizumab...
April 23, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38649557/pan-cancer-analysis-of-the-prognostic-and-immunological-role-of-tomm40-to-identify-its-function-in-breast-cancer
#19
JOURNAL ARTICLE
Yaqing Zhou, Xing Wei, Lijun Jia, Weimiao Li, Shuqun Zhang, Yonglin Zhao
Breast cancer (BRCA) is currently the most commonly diagnosed malignancy in women worldwide. Previous studies have demonstrated that mitophagy is important for the prevention and treatment of BRCA. However, few studies have focused on the individual mitochondrial autophagy-related genes (MARG) in human cancers. Based on bioinformatics analyses, TOMM40 was identified as a prognostic DEMARG (PDEMARGs); Kaplan-Meier (KM) survival analysis also indicates that TOMM40 can be useful as a prognostic indicator in BRCAs, with patients in the high expression group having a poorer prognosis...
April 22, 2024: Biochemical Genetics
https://read.qxmd.com/read/38649497/-clinical-approach-for-solid-intraocular-metastases
#20
REVIEW
Neele Babst, Stefanie Gniesmer, Svenja Rebecca Sonntag, Olga Furashova, Gabriele Krestanova, Ludwig Maximilian Heindl, Martin Müller, Salvatore Grisanti, Vinodh Kakkassery
BACKGROUND: Intraocular metastases arising from solid tumors are found in approximately 2% of patients with metastatic tumor diseases and are therefore more frequent than originally assumed. They often affect the uvea and are associated with a poor prognosis. Due to the difficult diagnosis and an inconsistent treatment regimen, ophthalmologists have a special responsibility here. OBJECTIVE: This article gives a summary of the various types of intraocular metastases with respect to clinical features, diagnostics, treatment and prognosis as well as recommendations for follow-up care...
April 22, 2024: Ophthalmologie
keyword
keyword
158568
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.